APOE-related biomarker profiles in non-pathological aging and early phases of Alzheimer's disease

Neuroscience and Biobehavioral Reviews

Volumn 37, Issue 8, 2013, Pages 1322-1335

  Reinvang, Ivar ^a   Espeseth, Thomas ^a,b   Westlye, Lars Tjelta ^a,b  

^a UNIVERSITY OF OSLO   (Norway)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

Alzheimer's disease; ApoE; Cognition; Imaging; Mild cognitive impairment; Neurodegeneration; White matter integrity

Indexed keywords

AMYLOID; AMYLOID BETA PROTEIN; APOLIPOPROTEIN E; BIOLOGICAL MARKER; FLUORODEOXYGLUCOSE;

AGING; ALZHEIMER DISEASE; APOE GENE; BRAIN FUNCTION; CHOLINERGIC SYSTEM; COGNITION; DIFFUSION TENSOR IMAGING; ELECTROENCEPHALOGRAM; ENZYME REGULATION; FUNCTIONAL MAGNETIC RESONANCE IMAGING; GENE; GENE ACTIVITY; GENE FUNCTION; GENE INTERACTION; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENOTYPE; HETEROZYGOTE; HUMAN; IMAGE ANALYSIS; IMAGE DISPLAY; IN VIVO STUDY; MITOCHONDRION; MORPHOLOGY; MULTIINFARCT DEMENTIA; MYELINATION; NERVE DEGENERATION; NEUROIMAGING; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; VASCULAR DISEASE;

AD; ALZHEIMER'S DISEASE; APOE; APOLIPOPROTEIN E GENE; APOLIPOPROTEIN E PROTEIN; AXD; AXONAL DIFFUSIVITY; CAA; CBF; CEREBRAL AMYLOID ANGIOPATHY; CEREBRAL BLOOD FLOW; CEREBROSPINAL FLUID; CHOLINERGIC RECEPTOR NEURAL NICOTINIC ALPHA CHAIN 4 GENE; CHRNA4; COGNITION; CSF; DEFAULT-MODE NETWORK; DIFFUSION TENSOR IMAGING; DMN; DTI; FA; FC; FDG; FLUORIDE-DEOXYGLUCOSE; FMRI; FRACTIONAL ANISOTROPY; FUNCTIONAL CONNECTIVITY; FUNCTIONAL MRI; GENOME WIDE ASSOCIATION SCAN; GWAS; IMAGING; MAGNETIC RESONANCE IMAGING; MCI; MD; MEAN DIFFUSIVITY; MILD COGNITIVE IMPAIRMENT; MRI; NBM; NEURODEGENERATION; NUCLEUS BASALIS MEYNERT; PET; PIB; PITTSBURGH SUBSTANCE B; POSITRON EMISSION TOMOGRAPHY; RADIAL DIFFUSIVITY; RD; RESTING STATE NETWORKS; RSNS; VBM; VOXEL BASED MORPHOMETRY; WHITE MATTER INTEGRITY;

AGING; ALLELES; ALZHEIMER DISEASE; APOLIPOPROTEINS E; BIOLOGICAL MARKERS; BRAIN; GENOTYPE; HUMANS; NEUROIMAGING;

EID: 84879719066     PISSN: 01497634     EISSN: 18737528     Source Type: Journal    
DOI: 10.1016/j.neubiorev.2013.05.006     Document Type: Review

References (158)

1. Aizenstein H.J., Nebes R.D., Saxton J.A., Price J.C., Mathis C.A., Tsopelas N.D., Ziolko S.K., James J.A., Snitz B.E., Houck P.R., Bi W., Cohen A.D., Lopresti B.J., DeKosky S.T., Halligan E.M., Klunk W.E. Frequent amyloid deposition without significant cognitive impairment among the elderly. Arch. Neurol. 2008, 65:1509-1517.
2. Alexander G.E., Bergfield K.L., Chen K., Reiman E.M., Hanson K.D., Lin L., Bandy D., Caselli R.J., Moeller J.R. Gray matter network associated with risk for Alzheimer's disease in young to middle-aged adults. Neurobiol. Aging 2012, 33:2723-2732.
3. Allen S.J., MacGowan S.H., Tyler S., Wilcock G.K., Robertson A.G., Holden P.H., Smith S.K., Dawbarn D. Reduced cholinergic function in normal and Alzheimer's disease brain is associated with apolipoprotein E4 genotype. Neurosci. Lett. 1997, 239:33-36.
4. Andersson C., Blennow K., Johansson S.E., Almkvist O., Engfeldt P., Lindau M., Eriksdotter-Jonhagen M. Differential CSF biomarker levels in APOE-epsilon4-positive and -negative patients with memory impairment. Dement. Geriatr. Cogn. Disord. 2007, 23:87-95.
5. Bartzokis G., Lu P.H., Geschwind D.H., Edwards N., Mintz J., Cummings J.L. Apolipoprotein E genotype and age-related myelin breakdown in healthy individuals: implications for cognitive decline and dementia. Arch. Gen. Psychiatry 2006, 63:63-72.
6. Bartzokis G., Lu P.H., Geschwind D.H., Tingus K., Huang D., Mendez M.F., Edwards N., Mintz J. Apolipoprotein E affects both myelin breakdown and cognition: implications for age-related trajectories of decline into dementia. Biol. Psychiatry 2007, 62:1380-1387.
7. Bartzokis G. Alzheimer's disease as homeostatic responses to age-related myelin breakdown. Neurobiol. Aging 2011, 32:1341-1371.
8. Bartzokis G., Lu P.H., Heydari P., Couvrette A., Lee G.J., Kalashyan G., Freeman F., Grinstead J.W., Villablanca P., Finn J.P., Mintz J., Alger J.R., Altshuler L.L. Multimodal magnetic resonance imaging assessment of white matter aging trajectories over the lifespan of healthy individuals. Biol. Psychiatry 2012, 72:1026-1034.
9. Bell R.D., Winkler E.A., Singh I., Sagare A.P., Deane R., Wu Z., Holtzman D.M., Betsholtz C., Armulik A., Sallstrom J., Berk B.C., Zlokovic B.V. Apolipoprotein E controls cerebrovascular integrity via cyclophilin A. Nature 2012, 485:512-516.
10. Bendlin B.B., Ries M.L., Canu E., Sodhi A., Lazar M., Alexander A.L., Carlsson C.M., Sager M.A., Asthana S., Johnson S.C. White matter is altered with parental family history of Alzheimer's disease. Alzheimers Dement. 2010, 6:394-403.
11. Biswal B., Yetkin F.Z., Haughton V.M., Hyde J.S. Functional connectivity in the motor cortex of resting human brain using echo-planar MRI. Magn. Reson. Med. 1995, 34:537-541.
12. Bloss C.S., Delis D.C., Salmon D.P., Bondi M.W. Decreased cognition in children with risk factors for Alzheimer's disease. Biol. Psychiatry 2008, 64:904-906.
13. Bookheimer S., Burggren A. APOE-4 genotype and neurophysiological vulnerability to Alzheimer's and cognitive aging. Annu. Rev. Clin. Psychol. 2009, 5:343-362.
14. Braak H., Braak E. Frequency of stages of Alzheimer-related lesions in different age categories. Neurobiol. Aging 1997, 18:351-357.
15. Brainerd C.J., Reyna V.F., Petersen R.C., Smith G.E., Taub E.S. Is the apolipoprotein e genotype a biomarker for mild cognitive impairment? Findings from a nationally representative study. Neuropsychology 2011, 25:679-689.
16. Brown J.A., Terashima K.H., Burggren A.C., Ercoli L.M., Miller K.J., Small G.W., Bookheimer S.Y. Brain network local interconnectivity loss in aging APOE-4 allele carriers. Proc. Natl. Acad. Sci. U. S. A. 2011, 108:20760-20765.
17. Bu G. Apolipoprotein E and its receptors in Alzheimer's disease: pathways, pathogenesis and therapy. Nat. Rev. Neurosci. 2009, 10:333-344.
18. Buckner R.L., Andrews-Hanna J.R., Schacter D.L. The brain's default network: anatomy, function, and relevance to disease. Ann. N. Y. Acad. Sci. 2008, 1124:1-38.
19. Budde M.D., Xie M., Cross A.H., Song S.K. Axial diffusivity is the primary correlate of axonal injury in the experimental autoimmune encephalomyelitis spinal cord: a quantitative pixelwise analysis. J. Neurosci. 2009, 29:2805-2813.
20. Bunce D., Anstey K.J., Cherbuin N., Gautam P., Sachdev P., Easteal S. APOE genotype and entorhinal cortex volume in non-demented community-dwelling adults in midlife and early old age. J. Alzheimers. Dis. 2012, 30:935-942.
21. Burghaus L., Schutz U., Krempel U., de Vos R.A., Jansen Steur E.N., Wevers A., Lindstrom J., Schroder H. Quantitative assessment of nicotinic acetylcholine receptor proteins in the cerebral cortex of Alzheimer patients. Brain Res. Mol. Brain Res. 2000, 76:385-388.
22. Caselli R.J., Chen K., Lee W., Alexander G.E., Reiman E.M. Correlating cerebral hypometabolism with future memory decline in subsequent converters to amnestic pre-mild cognitive impairment. Arch. Neurol. 2008, 65:1231-1236.
23. Caselli R.J., Dueck A.C., Osborne D., Sabbagh M.N., Connor D.J., Ahern G.L., Baxter L.C., Rapcsak S.Z., Shi J., Woodruff B.K., Locke D.E., Snyder C.H., Alexander G.E., Rademakers R., Reiman E.M. Longitudinal modeling of age-related memory decline and the APOE epsilon4 effect. N. Engl. J. Med. 2009, 361:255-263.
24. Caselli R.J., Walker D., Sue L., Sabbagh M., Beach T. Amyloid load in nondemented brains correlates with APOE e4. Neurosci. Lett. 2010, 473:168-171.
25. Cechetti F., Pagnussat A.S., Worm P.V., Elsner V.R., Ben J., da Costa M.S., Mestriner R., Weis S.N., Netto C.A. Chronic brain hypoperfusion causes early glial activation and neuronal death, and subsequent long-term memory impairment. Brain Res. Bull. 2012, 87:109-116.
26. Chen K., Reiman E.M., Alexander G.E., Caselli R.J., Gerkin R., Bandy D., Domb A., Osborne D., Fox N., Crum W.R., Saunders A.M., Hardy J. Correlations between apolipoprotein E epsilon4 gene dose and whole brain atrophy rates. Am. J. Psychiatry 2007, 164:916-921.
27. Cherbuin N., Leach L.S., Christensen H., Anstey K.J. Neuroimaging and APOE genotype: a systematic qualitative review. Dement. Geriatr. Cogn. Disord. 2007, 24:348-362.
28. Chetelat G., Villemagne V.L., Pike K.E., Ellis K.A., Bourgeat P., Jones G., O'Keefe G.J., Salvado O., Szoeke C., Martins R.N., Ames D., Masters C.L., Rowe C.C. Independent contribution of temporal beta-amyloid deposition to memory decline in the pre-dementia phase of Alzheimer's disease. Brain 2011, 134:798-807.
29. Chiang G.C., Insel P.S., Tosun D., Schuff N., Truran-Sacrey D., Raptentsetsang S.T., Thompson P.M., Reiman E.M., Jack C.R., Fox N.C., Jagust W.J., Harvey D.J., Beckett L.A., Gamst A., Aisen P.S., Petersen R.C., Weiner M.W. Impact of apolipoprotein E4-cerebrospinal fluid beta-amyloid interaction on hippocampal volume loss over 1 year in mild cognitive impairment. Alzheimers Dement. 2011, 7:514-520.
30. Christensen H., Batterham P.J., Mackinnon A.J., Jorm A.F., Mack H.A., Mather K.A., Anstey K.J., Sachdev P.S., Easteal S. The association of APOE genotype and cognitive decline in interaction with risk factors in a 65-69 year old community sample. BMC Geriatr. 2008, 8:14.
31. Conejero-Goldberg C., Hyde T.M., Chen S., Dreses-Werringloer U., Herman M.M., Kleinman J.E., Davies P., Goldberg T.E. Molecular signatures in post-mortem brain tissue of younger individuals at high risk for Alzheimer's disease as based on APOE genotype. Mol. Psychiatry 2011, 16:836-847.
32. Corder E.H., Saunders A.M., Strittmatter W.J., Schmechel D.E., Gaskell P.C., Small G.W., Roses A.D., Haines J.L., Pericak-Vance M.A. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 1993, 261:921-923.
33. Desikan R.S., McEvoy L.K., Holland D., Thompson W.K., Brewer J.B., Aisen P.S., Andreassen O.A., Hyman B.T., Sperling R.A., Dale A.M. Apolipoprotein E {varepsilon}4 does not modulate amyloid-beta-associated neurodegeneration in preclinical Alzheimer Disease. Am. J. Neuroradiol. 2013, 34(3):505-510.
34. Donix M., Burggren A.C., Suthana N.A., Siddarth P., Ekstrom A.D., Krupa A.K., Jones M., Rao A., Martin-Harris L., Ercoli L.M., Miller K.J., Small G.W., Bookheimer S.Y. Longitudinal changes in medial temporal cortical thickness in normal subjects with the APOE-4 polymorphism. Neuroimage 2010, 53:37-43.
35. Donix M., Small G.W., Bookheimer S.Y. Family history and APOE-4 genetic risk in Alzheimer's disease. Neuropsychol. Rev. 2012, 22:298-309.
36. Drzezga A., Grimmer T., Riemenschneider M., Lautenschlager N., Siebner H., Alexopoulus P., Minoshima S., Schwaiger M., Kurz A. Prediction of individual clinical outcome in MCI by means of genetic assessment and (18)F-FDG PET. J. Nucl. Med. 2005, 46:1625-1632.
37. Eddins D., Klein R.C., Yakel J.L., Levin E.D. Hippocampal infusions of apolipoprotein E peptides induce long-lasting cognitive impairment. Brain Res. Bull. 2009, 79:111-115.
38. Espeseth T., Greenwood P.M., Reinvang I., Fjell A.M., Walhovd K.B., Westlye L.T., Wehling E., Lundervold A., Rootwelt H., Parasuraman R. Interactive effects of APOE and CHRNA4 on attention and white matter volume in healthy middle-aged and older adults. Cogn. Affect. Behav. Neurosci. 2006, 6:31-43.
39. Espeseth T., Westlye L.T., Fjell A.M., Walhovd K.B., Rootwelt H., Reinvang I. Accelerated age-related cortical thinning in healthy carriers of apolipoprotein E epsilon 4. Neurobiol. Aging 2008, 29:329-340.
40. Espeseth T., Westlye L.T., Walhovd K.B., Fjell A.M., Endestad T., Rootwelt H., Reinvang I. Apolipoprotein E epsilon4-related thickening of the cerebral cortex modulates selective attention. Neurobiol. Aging 2012, 33:304-322.
41. Fancy S.P., Chan J.R., Baranzini S.E., Franklin R.J., Rowitch D.H. Myelin regeneration: a recapitulation of development?. Annu. Rev. Neurosci. 2011, 34:21-43.
42. Farrall A.J., Wardlaw J.M. Blood-brain barrier: ageing and microvascular disease-systematic review and meta-analysis. Neurobiol. Aging 2009, 30:337-352.
43. Fennema-Notestine C., Panizzon M.S., Thompson W.R., Chen C.H., Eyler L.T., Fischl B., Franz C.E., Grant M.D., Jak A.J., Jernigan T.L., Lyons M.J., Neale M.C., Seidman L.J., Tsuang M.T., Xian H., Dale A.M., Kremen W.S. Presence of ApoE epsilon4 allele associated with thinner frontal cortex in middle age. J. Alzheimers Dis. 2011, 26(Suppl. 3):49-60.
44. Filippini N., MacIntosh B.J., Hough M.G., Goodwin G.M., Frisoni G.B., Smith S.M., Matthews P.M., Beckmann C.F., Mackay C.E. Distinct patterns of brain activity in young carriers of the APOE-epsilon4 allele. Proc. Nat. Acad. Sci. U. S. A. 2009, 106:7209-7214.
45. Fischl B., Salat D.H., Busa E., Albert M., Dieterich M., Haselgrove C., van der Kouwe A., Killiany R., Kennedy D., Klaveness S., Montillo A., Makris N., Rosen B., Dale A.M. Whole brain segmentation: automated labeling of neuroanatomical structures in the human brain. Neuron 2002, 33:341-355.
46. Fjell A.M., Westlye L.T., Amlien I.K., Walhovd K.B. Reduced white matter integrity is related to cognitive instability. J. Neurosci. 2011, 31:18060-18072.
47. Flory J.D., Manuck S.B., Ferrell R.E., Ryan C.M., Muldoon M.F. Memory performance and the apolipoprotein E polymorphism in a community sample of middle-aged adults. Am. J. Med. Genet. 2000, 96:707-711.
48. Genin E., Hannequin D., Wallon D., Sleegers K., Hiltunen M., Combarros O., Bullido M.J., Engelborghs S., De D.P., Berr C., Pasquier F., Dubois B., Tognoni G., Fievet N., Brouwers N., Bettens K., Arosio B., Coto E., Del Z.M., Mateo I., Epelbaum J., Frank-Garcia A., Helisalmi S., Porcellini E., Pilotto A., Forti P., Ferri R., Scarpini E., Siciliano G., Solfrizzi V., Sorbi S., Spalletta G., Valdivieso F., Vepsalainen S., Alvarez V., Bosco P., Mancuso M., Panza F., Nacmias B., Bossu P., Hanon O., Piccardi P., Annoni G., Seripa D., Galimberti D., Licastro F., Soininen H., Dartigues J.F., Kamboh M.I., Van B.C., Lambert J.C., Amouyel P., Campion D. APOE and Alzheimer disease: a major gene with semi-dominant inheritance. Mol. Psychiatry 2011, 16:903-907.
49. Gerdes L.U. The common polymorphism of apolipoprotein E: geographical aspects and new pathophysiological relations. Clin. Chem. Lab. Med. 2003, 41:628-631.
50. Geula C., Mesulam M.M. Systematic regional variations in the loss of cortical cholinergic fibers in Alzheimer's disease. Cereb. Cortex 1996, 6:165-177.
51. Greenwood P.M., Sunderland T., Friz J.L., Parasuraman R. Genetics and visual attention: selective deficits in healthy adult carriers of the epsilon 4 allele of the apolipoprotein E gene. Proc. Natl. Acad. Sci. U. S. A. 2000, 97:11661-11666.
52. Greenwood P.M., Lambert C., Sunderland T., Parasuraman R. Effects of apolipoprotein E genotype on spatial attention, working memory, and their interaction in healthy, middle-aged adults: results From the National Institute of Mental Health's BIOCARD study. Neuropsychology 2005, 19:199-211.
53. Greicius M.D., Srivastava G., Reiss A.L., Menon V. Default-mode network activity distinguishes Alzheimer's disease from healthy aging: evidence from functional MRI. Proc. Natl. Acad. Sci. U. S. A. 2004, 101:4637-4642.
54. Grinberg L.T., Thal D.R. Vascular pathology in the aged human brain. Acta Neuropathol. 2010, 119:277-290.
55. Grothe M., Zaborszky L., Atienza M., Gil-Neciga E., Rodriguez-Romero R., Teipel S.J., Amunts K., Suarez-Gonzalez A., Cantero J.L. Reduction of basal forebrain cholinergic system parallels cognitive impairment in patients at high risk of developing Alzheimer's disease. Cereb. Cortex 2010, 20:1685-1695.
56. Grothe M., Heinsen H., Teipel S.J. Atrophy of the cholinergic Basal forebrain over the adult age range and in early stages of Alzheimer's disease. Biol. Psychiatry 2012, 71:805-813.
57. Haense C., Kalbe E., Herholz K., Hohmann C., Neumaier B., Krais R., Heiss W.D. Cholinergic system function and cognition in mild cognitive impairment. Neurobiol. Aging 2012, 33:867-877.
58. Hall A.M., Moore R.Y., Lopez O.L., Kuller L., Becker J.T. Basal forebrain atrophy is a presymptomatic marker for Alzheimer's disease. Alzheimers Dement. 2008, 4:271-279.
59. He J., Farias S., Martinez O., Reed B., Mungas D., Decarli C. Differences in brain volume, hippocampal volume, cerebrovascular risk factors, and apolipoprotein E4 among mild cognitive impairment subtypes. Arch. Neurol. 2009, 66:1393-1399.
60. Heise V., Filippini N., Ebmeier K.P., Mackay C.E. The APOE varepsilon4 allele modulates brain white matter integrity in healthy adults. Mol. Psychiatry 2011, 16:908-916.
61. Herrup K. Reimagining Alzheimer's disease-an age-based hypothesis. J. Neurosci. 2010, 30:16755-16762.
62. Holtzman D.M., Herz J., Bu G. Apolipoprotein e and apolipoprotein e receptors: normal biology and roles in Alzheimer disease. Cold Spring Harb. Perspect. Med. 2012, 2:a006312.
63. Honea R.A., Vidoni E., Harsha A., Burns J.M. Impact of APOE on the healthy aging brain: a voxel-based MRI and DTI study. J. Alzheimers Dis. 2009, 18:553-564.
64. Horstmann A., Frisch S., Jentzsch R.T., Muller K., Villringer A., Schroeter M.L. Resuscitating the heart but losing the brain: brain atrophy in the aftermath of cardiac arrest. Neurology 2010, 74:306-312.
65. Hyman B.T. Amyloid-dependent and amyloid-independent stages of Alzheimer disease. Arch. Neurol. 2011, 68:1062-1064.
66. Jack C.R., Lowe V.J., Senjem M.L., Weigand S.D., Kemp B.J., Shiung M.M., Knopman D.S., Boeve B.F., Klunk W.E., Mathis C.A., Petersen R.C. 11C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment. Brain 2008, 131:665-680.
67. Jack C.R., Knopman D.S., Jagust W.J., Shaw L.M., Aisen P.S., Weiner M.W., Petersen R.C., Trojanowski J.Q. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol. 2010, 9:119-128.
68. Jones E.L., Kalaria R.N., Sharp S.I., O'Brien J.T., Francis P.T., Ballard C.G. Genetic associations of autopsy-confirmed vascular dementia subtypes. Dement. Geriatr. Cogn. Disord. 2011, 31:247-253.
69. Jorm A.F., Mather K.A., Butterworth P., Anstey K.J., Christensen H., Easteal S. APOE genotype and cognitive functioning in a large age-stratified population sample. Neuropsychology 2007, 21:1-8.
70. Kadir A., Almkvist O., Wall A., Langstrom B., Nordberg A. PET imaging of cortical 11C-nicotine binding correlates with the cognitive function of attention in Alzheimer's disease. Psychopharmacology (Berl.) 2006, 188:509-520.
71. Kalaria R.N., Maestre G.E., Arizaga R., Friedland R.P., Galasko D., Hall K., Luchsinger J.A., Ogunniyi A., Perry E.K., Potocnik F., Prince M., Stewart R., Wimo A., Zhang Z.X., Antuono P. Alzheimer's disease and vascular dementia in developing countries: prevalence, management, and risk factors. Lancet Neurol. 2008, 7:812-826.
72. Kantarci K., Lowe V., Przybelski S.A., Weigand S.D., Senjem M.L., Ivnik R.J., Preboske G.M., Roberts R., Geda Y.E., Boeve B.F., Knopman D.S., Petersen R.C., Jack C.R. APOE modifies the association between Abeta load and cognition in cognitively normal older adults. Neurology 2012, 78:232-240.
73. Kim J., Basak J.M., Holtzman D.M. The role of apolipoprotein E in Alzheimer's disease. Neuron 2009, 63:287-303.
74. Klein R.C., Yakel J.L. Inhibition of nicotinic acetylcholine receptors by apolipoprotein E-derived peptides in rat hippocampal slices. Neuroscience 2004, 127:563-567.
75. Knickmeyer R.C., Wang J., Zhu H., Geng X., Woolson S., Hamer R.M., Konneker T., Lin W., Styner M., Gilmore J.H. Common variants in psychiatric risk genes predict brain structure at birth. Cereb. Cortex 2013, E-pub ahead of print.
76. Kok E., Haikonen S., Luoto T., Huhtala H., Goebeler S., Haapasalo H., Karhunen P.J. Apolipoprotein E-dependent accumulation of Alzheimer disease-related lesions begins in middle age. Ann. Neurol. 2009, 65:650-657.
77. Lai M.K., Tsang S.W., Garcia-Alloza M., Minger S.L., Nicoll J.A., Esiri M.M., Wong P.T., Chen C.P., Ramirez M.J., Francis P.T. Selective effects of the APOE epsilon4 allele on presynaptic cholinergic markers in the neocortex of Alzheimer's disease. Neurobiol. Dis. 2006, 22:555-561.
78. Luchsinger J.A., Brickman A.M., Reitz C., Cho S.J., Schupf N., Manly J.J., Tang M.X., Small S.A., Mayeux R., Decarli C., Brown T.R. Subclinical cerebrovascular disease in mild cognitive impairment. Neurology 2009, 73:450-456.
79. Luckhaus C., Cohnen M., Fluss M.O., Janner M., Grass-Kapanke B., Teipel S.J., Grothe M., Hampel H., Peters O., Kornhuber J., Maier W., Supprian T., Gaebel W., Modder U., Wittsack H.J. The relation of regional cerebral perfusion and atrophy in mild cognitive impairment (MCI) and early Alzheimer's dementia. Psychiatry Res. 2010, 183:44-51.
80. Machulda M.M., Jones D.T., Vemuri P., McDade E., Avula R., Przybelski S., Boeve B.F., Knopman D.S., Petersen R.C., Jack C.R. Effect of APOE epsilon4 status on intrinsic network connectivity in cognitively normal elderly subjects. Arch. Neurol. 2011, 68:1131-1136.
81. Madden D.J., Bennett I.J., Song A.W. Cerebral white matter integrity and cognitive aging: contributions from diffusion tensor imaging. Neuropsychol. Rev. 2009, 19:415-435.
82. Mahley R.W., Weisgraber K.H., Huang Y. Apolipoprotein E4: a causative factor and therapeutic target in neuropathology, including Alzheimer's disease. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:5644-5651.
83. Mahley R.W., Huang Y. Alzheimer disease: multiple causes, multiple effects of apolipoprotein E4, and multiple therapeutic approaches. Ann. Neurol. 2009, 65:623-625.
84. Margulies D.S., Bottger J., Long X., Lv Y., Kelly C., Schafer A., Goldhahn D., Abbushi A., Milham M.P., Lohmann G., Villringer A. Resting developments: a review of fMRI post-processing methodologies for spontaneous brain activity. MAGMA 2010, 23:289-307.
85. Marner L., Nyengaard J.R., Tang Y., Pakkenberg B. Marked loss of myelinated nerve fibers in the human brain with age. J. Comp. Neurol. 2003, 462:144-152.
86. Martin A.J., Friston K.J., Colebatch J.G., Frackowiak R.S. Decreases in regional cerebral blood flow with normal aging. J. Cereb. Blood Flow Metab. 1991, 11:684-689.
87. Martin-Ruiz C.M., Court J.A., Molnar E., Lee M., Gotti C., Mamalaki A., Tsouloufis T., Tzartos S., Ballard C., Perry R.H., Perry E.K. Alpha4 but not alpha3 and alpha7 nicotinic acetylcholine receptor subunits are lost from the temporal cortex in Alzheimer's disease. J. Neurochem. 1999, 73:1635-1640.
88. Martin-Ruiz C., Court J., Lee M., Piggott M., Johnson M., Ballard C., Kalaria R., Perry R., Perry E. Nicotinic receptors in dementia of Alzheimer, Lewy body and vascular types. Acta Neurol. Scand. Suppl. 2000, 176:34-41.
89. Mayeux R. Apolipoprotein E, Alzheimer disease, and African Americans. Arch. Neurol. 2003, 60:161-163.
90. Mitsis E.M., Cosgrove K.P., Staley J.K., Bois F., Frohlich E.B., Tamagnan G.D., Estok K.M., Seibyl J.P., van Dyck C.H. Age-related decline in nicotinic receptor availability with [(123)I]5-IA-85380 SPECT. Neurobiol. Aging 2009, 30:1490-1497.
91. Mondadori C.R., de Quervain D.J., Buchmann A., Mustovic H., Wollmer M.A., Schmidt C.F., Boesiger P., Hock C., Nitsch R.M., Papassotiropoulos A., Henke K. Better memory and neural efficiency in young apolipoprotein E epsilon4 carriers. Cereb. Cortex 2007, 17:1934-1947.
92. Morris J.C., Roe C.M., Xiong C., Fagan A.M., Goate A.M., Holtzman D.M., Mintun M.A. APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging. Ann. Neurol. 2010, 67:122-131.
93. Nierenberg J., Pomara N., Hoptman M.J., Sidtis J.J., Ardekani B.A., Lim K.O. Abnormal white matter integrity in healthy apolipoprotein E epsilon4 carriers. Neuroreport 2005, 16:1369-1372.
94. Penke L., Maniega S.M., Bastin M.E., Valdes Hernandez M.C., Murray C., Royle N.A., Starr J.M., Wardlaw J.M., Deary I.J. Brain white matter tract integrity as a neural foundation for general intelligence. Mol. Psychiatry 2012, 17:1026-1030.
95. Persson J., Lind J., Larsson A., Ingvar M., Cruts M., Van B.C., Adolfsson R., Nilsson L.G., Nyberg L. Altered brain white matter integrity in healthy carriers of the APOE epsilon4 allele: a risk for AD?. Neurology 2006, 66:1029-1033.
96. Peters A., Kemper T. A review of the structural alterations in the cerebral hemispheres of the aging rhesus monkey. Neurobiol. Aging 2012, 33:2357-2372.
97. Peters A., Sethares C. Is there remyelination during aging of the primate central nervous system?. J. Comp. Neurol. 2003, 460:238-254.
98. Petersen R.C., Smith G.E., Waring S.C., Ivnik R.J., Tangalos E.G., Kokmen E. Mild cognitive impairment: clinical characterization and outcome. Arch. Neurol. 1999, 56:303-308.
99. Pfrieger F.W. Cholesterol homeostasis and function in neurons of the central nervous system. Cell Mol. Life Sci. 2003, 60:1158-1171.
100. Pike K.E., Ellis K.A., Villemagne V.L., Good N., Chetelat G., Ames D., Szoeke C., Laws S.M., Verdile G., Martins R.N., Masters C.L., Rowe C.C. Cognition and beta-amyloid in preclinical Alzheimer's disease: data from the AIBL study. Neuropsychologia 2011, 49:2384-2390.
101. Poels M.M., Vernooij M.W., Ikram M.A., Hofman A., Krestin G.P., van der Lugt A., Breteler M.M. Prevalence and risk factors of cerebral microbleeds: an update of the Rotterdam scan study. Stroke 2010, 41:S103-S106.
102. Poirier J., Delisle M.C., Quirion R., Aubert I., Farlow M., Lahiri D., Hui S., Bertrand P., Nalbantoglu J., Gilfix B.M., Gauthier S. Apolipoprotein E4 allele as a predictor of cholinergic deficits and treatment outcome in Alzheimer disease. Proc. Natl. Acad. Sci. U. S. A. 1995, 92:12260-12264.
103. Price J.L., Davis P.B., Morris J.C., White D.L. The distribution of tangles, plaques and related immunohistochemical markers in healthy aging and Alzheimer's disease. Neurobiol. Aging 1991, 12:295-312.
104. Raber J., Huang Y., Ashford J.W. ApoE genotype accounts for the vast majority of AD risk and AD pathology. Neurobiol. Aging 2004, 25:641-650.
105. Reiman E.M., Chen K., Alexander G.E., Caselli R.J., Bandy D., Osborne D., Saunders A.M., Hardy J. Functional brain abnormalities in young adults at genetic risk for late-onset Alzheimer's dementia. Proc. Natl. Acad. Sci. U. S. A. 2004, 101:284-289.
106. Reiman E.M., Chen K., Liu X., Bandy D., Yu M., Lee W., Ayutyanont N., Keppler J., Reeder S.A., Langbaum J.B., Alexander G.E., Klunk W.E., Mathis C.A., Price J.C., Aizenstein H.J., DeKosky S.T., Caselli R.J. Fibrillar amyloid-beta burden in cognitively normal people at 3 levels of genetic risk for Alzheimer's disease. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:6820-6825.
107. Reinvang I., Lundervold A.J., Wehling E., Rootwelt H., Espeseth T. Epistasis between APOE and nicotinic receptor gene CHRNA4 in age related cognitive function and decline. J. Int. Neuropsychol. Soc. 2010, 16:424-432.
108. Reinvang I., Winjevoll I.L., Rootwelt H., Espeseth T. Working memory deficits in healthy APOE epsilon 4 carriers. Neuropsychologia 2010, 48:566-573.
109. Rosen V.M., Bergeson J.L., Putnam K., Harwell A., Sunderland T. Working memory and apolipoprotein E: what's the connection?. Neuropsychologia 2002, 40:2226-2233.
110. Rowe C.C., Ellis K.A., Rimajova M., Bourgeat P., Pike K.E., Jones G., Fripp J., Tochon-Danguy H., Morandeau L., O'Keefe G., Price R., Raniga P., Robins P., Acosta O., Lenzo N., Szoeke C., Salvado O., Head R., Martins R., Masters C.L., Ames D., Villemagne V.L. Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging. Neurobiol. Aging 2010, 31:1275-1283.
111. Salami A., Eriksson J., Nilsson L.G., Nyberg L. Age-related white matter microstructural differences partly mediate age-related decline in processing speed but not cognition. Biochim. Biophys. Acta 2012, 1822:408-415.
112. Salehi A., Dubelaar E.J., Mulder M., Swaab D.F. Aggravated decrease in the activity of nucleus basalis neurons in Alzheimer's disease is apolipoprotein E-type dependent. Proc. Natl. Acad. Sci. U. S. A. 1998, 95:11445-11449.
113. Scarmeas N., Habeck C.G., Stern Y., Anderson K.E. APOE genotype and cerebral blood flow in healthy young individuals. JAMA 2003, 290:1581-1582.
114. Schliebs R., Arendt T. The cholinergic system in aging and neuronal degeneration. Behav. Brain Res. 2011, 221:555-563.
115. Schuff N., Woerner N., Boreta L., Kornfield T., Shaw L.M., Trojanowski J.Q., Thompson P.M., Jack C.R., Weiner M.W. MRI of hippocampal volume loss in early Alzheimer's disease in relation to ApoE genotype and biomarkers. Brain 2009, 132:1067-1077.
116. Shaw P., Lerch J.P., Pruessner J.C., Taylor K.N., Rose A.B., Greenstein D., Clasen L., Evans A., Rapoport J.L., Giedd J.N. Cortical morphology in children and adolescents with different apolipoprotein E gene polymorphisms: an observational study. Lancet Neurol. 2007, 6:494-500.
117. Sheline Y.I., Morris J.C., Snyder A.Z., Price J.L., Yan Z., D'Angelo G., Liu C., Dixit S., Benzinger T., Fagan A., Goate A., Mintun M.A. APOE4 allele disrupts resting state fMRI connectivity in the absence of amyloid plaques or decreased CSF Abeta42. J. Neurosci. 2010, 30:17035-17040.
118. Siegel J.A., Benice T.S., Van M.P., Park B.S., Raber J. Acetylcholine receptor and behavioral deficits in mice lacking apolipoprotein E. Neurobiol. Aging 2011, 32:75-84.
119. Small G.W., Siddarth P., Burggren A.C., Kepe V., Ercoli L.M., Miller K.J., Lavretsky H., Thompson P.M., Cole G.M., Huang S.C., Phelps M.E., Bookheimer S.Y., Barrio J.R. Influence of cognitive status, age, and APOE-4 genetic risk on brain FDDNP positron-emission tomography imaging in persons without dementia. Arch. Gen. Psychiatry 2009, 66:81-87.
120. Smith S.M., Fox P.T., Miller K.L., Glahn D.C., Fox P.M., Mackay C.E., Filippini N., Watkins K.E., Toro R., Laird A.R., Beckmann C.F. Correspondence of the brain's functional architecture during activation and rest. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:13040-13045.
121. Sperling R.A., Laviolette P.S., O'Keefe K., O'Brien J., Rentz D.M., Pihlajamaki M., Marshall G., Hyman B.T., Selkoe D.J., Hedden T., Buckner R.L., Becker J.A., Johnson K.A. Amyloid deposition is associated with impaired default network function in older persons without dementia. Neuron 2009, 63:178-188.
122. Sperling R.A., Aisen P.S., Beckett L.A., Bennett D.A., Craft S., Fagan A.M., Iwatsubo T., Jack C.R., Kaye J., Montine T.J., Park D.C., Reiman E.M., Rowe C.C., Siemers E., Stern Y., Yaffe K., Carrillo M.C., Thies B., Morrison-Bogorad M., Wagster M.V., Phelps C.H. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011, 7:280-292.
123. Stein J.L., Medland S.E., Vasquez A.A., Hibar D.P., Senstad R.E., Winkler A.M., Toro R., Appel K., Bartecek R., Bergmann O., Bernard M., Brown A.A., Cannon D.M., Chakravarty M.M., Christoforou A., Domin M., Grimm O., Hollinshead M., Holmes A.J., Homuth G., Hottenga J.J., Langan C., Lopez L.M., Hansell N.K., Hwang K.S., Kim S., Laje G., Lee P.H., Liu X., Loth E., Lourdusamy A., Mattingsdal M., Mohnke S., Maniega S.M., Nho K., Nugent A.C., O'Brien C., Papmeyer M., Putz B., Ramasamy A., Rasmussen J., Rijpkema M., Risacher S.L., Roddey J.C., Rose E.J., Ryten M., Shen L., Sprooten E., Strengman E., Teumer A., Trabzuni D., Turner J., van E.K., van Erp T.G., van Tol M.J., Wittfeld K., Wolf C., Woudstra S., Aleman A., Alhusaini S., Almasy L., Binder E.B., Brohawn D.G., Cantor R.M., Carless M.A., Corvin A., Czisch M., Curran J.E., Davies G., de Almeida M.A., Delanty N., Depondt C., Duggirala R., Dyer T.D., Erk S., Fagerness J., Fox P.T., Freimer N.B., Gill M., Goring H.H., Hagler D.J., Hoehn D., Holsboer F., Hoogman M., Hosten N., Jahanshad N., Johnson M.P., Kasperaviciute D., Kent J.W., Kochunov P., Lancaster J.L., Lawrie S.M., Liewald D.C., Mandl R., Matarin M., Mattheisen M., Meisenzahl E., Melle I., Moses E.K., Muhleisen T.W., Nauck M., Nothen M.M., Olvera R.L., Pandolfo M., Pike G.B., Puls R., Reinvang I., Renteria M.E., Rietschel M., Roffman J.L., Royle N.A., Rujescu D., Savitz J., Schnack H.G., Schnell K., Seiferth N., Smith C., Steen V.M., Valdes Hernandez M.C., Van den Heuvel M., van der Wee N.J., Van Haren N.E., Veltman J.A., Volzke H., Walker R., Westlye L.T., Whelan C.D., Agartz I., Boomsma D.I., Cavalleri G.L., Dale A.M., Djurovic S., Drevets W.C., Hagoort P., Hall J., Heinz A., Jack C.R., Foroud T.M., Le H.S., Macciardi F., Montgomery G.W., Poline J.B., Porteous D.J., Sisodiya S.M., Starr J.M., Sussmann J., Toga A.W., Veltman D.J., Walter H., Weiner M.W., Bis J.C., Ikram M.A., Smith A.V., Gudnason V., Tzourio C., Vernooij M.W., Launer L.J., Decarli C., Seshadri S., Andreassen O.A., Apostolova L.G., Bastin M.E., Blangero J., Brunner H.G., Buckner R.L., Cichon S., Coppola G., de Zubicaray G.I., Deary I.J., Donohoe G., de Geus E.J., Espeseth T., Fernandez G., Glahn D.C., Grabe H.J., Hardy J., Hulshoff Pol H.E., Jenkinson M., Kahn R.S., McDonald C., McIntosh A.M., McMahon F.J., McMahon K.L., Meyer-Lindenberg A., Morris D.W., Muller-Myhsok B., Nichols T.E., Ophoff R.A., Paus T., Pausova Z., Penninx B.W., Potkin S.G., Samann P.G., Saykin A.J., Schumann G., Smoller J.W., Wardlaw J.M., Weale M.E., Martin N.G., Franke B., Wright M.J., Thompson P.M. Identification of common variants associated with human hippocampal and intracranial volumes. Nat. Genet. 2012, 44:552-561.
124. Stephan B.C., Hunter S., Harris D., Llewellyn D.J., Siervo M., Matthews F.E., Brayne C. The neuropathological profile of mild cognitive impairment (MCI): a systematic review. Mol. Psychiatry 2012, 17:1056-1076.
125. Storandt M., Mintun M.A., Head D., Morris J.C. Cognitive decline and brain volume loss as signatures of cerebral amyloid-beta peptide deposition identified with Pittsburgh compound B: cognitive decline associated with Abeta deposition. Arch. Neurol. 2009, 66:1476-1481.
126. Strittmatter W.J., Saunders A.M., Schmechel D., Pericak-Vance M., Enghild J., Salvesen G.S., Roses A.D. Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc. Natl. Acad. Sci. U. S. A. 1993, 90:1977-1981.
127. Tamnes C.K., Fjell A.M., Westlye L.T., Ostby Y., Walhovd K.B. Becoming consistent: developmental reductions in intraindividual variability in reaction time are related to white matter integrity. J. Neurosci. 2012, 32:972-982.
128. Taylor A.E., Guthrie P.A., Smith G.D., Golding J., Sattar N., Hingorani A.D., Deanfield J.E., Day I.N. IQ, educational attainment, memory and plasma lipids: associations with apolipoprotein E genotype in 5995 children. Biol. Psychiatry 2011, 70:152-158.
129. Teipel S.J., Meindl T., Grinberg L., Grothe M., Cantero J.L., Reiser M.F., Moller H.J., Heinsen H., Hampel H. The cholinergic system in mild cognitive impairment and Alzheimer's disease: an in vivo MRI and DTI study. Hum. Brain Mapp. 2011, 32:1349-1362.
130. Terriere E., Dempsey M.F., Herrmann L.L., Tierney K.M., Lonie J.A., O'Carroll R.E., Pimlott S., Wyper D.J., Herholz K., Ebmeier K.P. 5-(123)I-A-85380 binding to the alpha4beta2-nicotinic receptor in mild cognitive impairment. Neurobiol. Aging 2010, 31:1885-1893.
131. Thal D.R., Ghebremedhin E., Rub U., Yamaguchi H., Del T.K., Braak H. Two types of sporadic cerebral amyloid angiopathy. J. Neuropathol. Exp. Neurol. 2002, 61:282-293.
132. Thal D.R., Capetillo-Zarate E., Larionov S., Staufenbiel M., Zurbruegg S., Beckmann N. Capillary cerebral amyloid angiopathy is associated with vessel occlusion and cerebral blood flow disturbances. Neurobiol. Aging 2009, 30:1936-1948.
133. Thal D.R., Papassotiropoulos A., Saido T.C., Griffin W.S., Mrak R.E., Kolsch H., Del T.K., Attems J., Ghebremedhin E. Capillary cerebral amyloid angiopathy identifies a distinct APOE epsilon4-associated subtype of sporadic Alzheimer's disease. Acta Neuropathol. 2010, 120:169-183.
134. Thambisetty M., Beason-Held L., An Y., Kraut M.A., Resnick S.M. APOE epsilon4 genotype and longitudinal changes in cerebral blood flow in normal aging. Arch. Neurol. 2010, 67:93-98.
135. Tohgi H., Utsugisawa K., Yoshimura M., Nagane Y., Mihara M. Age-related changes in nicotinic acetylcholine receptor subunits alpha4 and beta2 messenger RNA expression in postmortem human frontal cortex and hippocampus. Neurosci. Lett. 1998, 245:139-142.
136. Tolboom N., van der Flier W.M., Yaqub M., Boellaard R., Verwey N.A., Blankenstein M.A., Windhorst A.D., Scheltens P., Lammertsma A.A., van Berckel B.N. Relationship of cerebrospinal fluid markers to 11C-PiB and 18F-FDDNP binding. J. Nucl. Med. 2009, 50:1464-1470.
137. Tosun D., Schuff N., Truran-Sacrey D., Shaw L.M., Trojanowski J.Q., Aisen P., Peterson R., Weiner M.W. Relations between brain tissue loss, CSF biomarkers, and the ApoE genetic profile: a longitudinal MRI study. Neurobiol. Aging 2010, 31:1340-1354.
138. Trachtenberg A.J., Filippini N., Cheeseman J., Duff E.P., Neville M.J., Ebmeier K.P., Karpe F., Mackay C.E. The effects of APOE on brain activity do not simply reflect the risk of Alzheimer's disease. Neurobiol. Aging 2012, 33:618.
139. Trachtenberg A.J., Filippini N., Ebmeier K.P., Smith S.M., Karpe F., Mackay C.E. The effects of APOE on the functional architecture of the resting brain. Neuroimage 2012, 59:565-572.
140. Trachtenberg A.J., Filippini N., Mackay C.E. The effects of APOE-epsilon4 on the BOLD response. Neurobiol. Aging 2012, 33:323-334.
141. Valla J., Yaari R., Wolf A.B., Kusne Y., Beach T.G., Roher A.E., Corneveaux J.J., Huentelman M.J., Caselli R.J., Reiman E.M. Reduced posterior cingulate mitochondrial activity in expired young adult carriers of the APOE epsilon4 allele, the major late-onset Alzheimer's susceptibility gene. J. Alzheimers Dis. 2010, 22:307-313.
142. Vemuri P., Wiste H.J., Weigand S.D., Knopman D.S., Shaw L.M., Trojanowski J.Q., Aisen P.S., Weiner M., Petersen R.C., Jack C.R. Effect of apolipoprotein E on biomarkers of amyloid load and neuronal pathology in Alzheimer disease. Ann. Neurol. 2010, 67:308-316.
143. Vemuri P., Wiste H.J., Weigand S.D., Knopman D.S., Trojanowski J.Q., Shaw L.M., Bernstein M.A., Aisen P.S., Weiner M., Petersen R.C., Jack C.R. Serial MRI and CSF biomarkers in normal aging, MCI, and AD. Neurology 2010, 75:143-151.
144. Verghese P.B., Castellano J.M., Holtzman D.M. Apolipoprotein E in Alzheimer's disease and other neurological disorders. Lancet Neurol. 2011, 10:241-252.
145. Villemagne V.L., Pike K.E., Chetelat G., Ellis K.A., Mulligan R.S., Bourgeat P., Ackermann U., Jones G., Szoeke C., Salvado O., Martins R., O'Keefe G., Mathis C.A., Klunk W.E., Ames D., Masters C.L., Rowe C.C. Longitudinal assessment of Abeta and cognition in aging and Alzheimer disease. Ann. Neurol. 2011, 69:181-192.
146. Vlassenko A.G., Mintun M.A., Xiong C., Sheline Y.I., Goate A.M., Benzinger T.L., Morris J.C. Amyloid-beta plaque growth in cognitively normal adults: longitudinal [11C]Pittsburgh compound B data. Ann. Neurol. 2011, 70:857-861.
147. Westlye E.T., Lundervold A., Rootwelt H., Lundervold A.J., Westlye L.T. Increased hippocampal default mode synchronization during rest in middle-aged and elderly APOE epsilon4 carriers: relationships with memory performance. J. Neurosci. 2011, 31:7775-7783.
148. Westlye L.T., Reinvang I., Rootwelt H., Espeseth T. Effects of APOE on brain white matter microstructure in healthy adults. Neurology 2012, 79:1961-1969.
149. Wheeler-Kingshott C.A., Cercignani M. About axial and radial diffusivities. Magn. Reson. Med. 2009, 61:1255-1260.
150. Whitwell J.L., Petersen R.C., Negash S., Weigand S.D., Kantarci K., Ivnik R.J., Knopman D.S., Boeve B.F., Smith G.E., Jack C.R. Patterns of atrophy differ among specific subtypes of mild cognitive impairment. Arch. Neurol. 2007, 64:1130-1138.
151. Wierenga C.E., Dev S.I., Shin D.D., Clark L.R., Bangen K.J., Jak A.J., Rissman R.A., Liu T.T., Salmon D.P., Bondi M.W. Effect of mild cognitive impairment and APOE genotype on resting cerebral blood flow and its association with cognition. J. Cereb. Blood Flow Metab. 2012, 32:1589-1599.
152. Wisdom N.M., Callahan J.L., Hawkins K.A. The effects of apolipoprotein E on non-impaired cognitive functioning: a meta-analysis. Neurobiol. Aging 2011, 32:63-74.
153. Wolk D.A., Dickerson B.C. Apolipoprotein E (APOE) genotype has dissociable effects on memory and attentional-executive network function in Alzheimer's disease. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:10256-10261.
154. Xiong C., Roe C.M., Buckles V., Fagan A., Holtzman D., Balota D., Duchek J., Storandt M., Mintun M., Grant E., Snyder A.Z., Head D., Benzinger T.L., Mettenburg J., Csernansky J., Morris J.C. Role of family history for Alzheimer biomarker abnormalities in the adult children study. Arch. Neurol. 2011, 68:1313-1319.
155. Yip A.G., McKee A.C., Green R.C., Wells J., Young H., Cupples L.A., Farrer L.A. APOE, vascular pathology, and the AD brain. Neurology 2005, 65:259-265.
156. Zade D., Beiser A., McGlinchey R., Au R., Seshadri S., Palumbo C., Wolf P.A., Decarli C., Milberg W. Interactive effects of apolipoprotein E type 4 genotype and cerebrovascular risk on neuropsychological performance and structural brain changes. J. Stroke Cerebrovasc. Dis. 2010, 19:261-268.
157. Zhang D., Raichle M.E. Disease and the brain's dark energy. Nat. Rev. Neurol. 2010, 6:15-28.
158. Zlokovic B.V. Neurovascular pathways to neurodegeneration in Alzheimer's disease and other disorders. Nat. Rev. Neurosci. 2011, 12:723-738.